Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...
This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...
French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...
In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...
TipRanks on MSN
Sanofi’s dupilumab study completion: Implications for asthma treatment and market impact
Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi recently completed a study titled ‘National, Multicenter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback